Abstract
Breast cancer (BC) is classified according to estrogen receptor (ER) status into ER+ and ER- tumors. ER+ tumors have a worse response to chemotherapy compared to ER- tumors. BCL-2, TP53, BAX and NF-ΚB are involved in drug resistance in the ER+ tumors. Recently it was shown that Cancer Stem Cells (CSCs) play an important role in drug resistance. In this study we tested the hypothesis that CSCs of the ER+ tumors resist drug through the overexpression of BCL-2, TP53, BAX and NF-ΚB. CSCs were isolated by anoikis resistance assay from MCF7 (ER+) and MDA-MB-231 (ER-) cell lines. Isolated CSCs were treated with doxorubicin (DOX) and the mRNA expression levels of BCL-2, TP53, BAX and NFKB were investigated by quantitative real time PCR (qPCR) with and without treatment. BCL-2, BAX and NF-ΚB showed decreased expression in MCF7 bulk cancer cells after DOX treatment whereas only BCL-2 and BAX showed decreased expression in MDA-MB-231 bulk cancer cells. Interestingly TP53 was the only gene showed a considerable increase in its expression in CSCs of the ER+ MCF7 cell line compared to bulk cancer cells. Moreover, TP53 was the only gene showing exceptionally higher level of expression in MCF7-CSCs compared to MDA-MB-231-CSCs. Our results sugg...Continue Reading
References
Jan 1, 1984·Pharmacology & Therapeutics·S C Barranco
Nov 1, 1996·Science·A A Beg, D Baltimore
Jun 20, 1998·British Journal of Haematology·A J McGahonT G Cotter
Sep 3, 1999·Breast Cancer Research and Treatment·L K Leung, T T Wang
Jan 5, 2000·Oncogene·N D Lakin, S P Jackson
Sep 8, 2000·Molecular Endocrinology·M RazandiE R Levin
Oct 19, 2001·Proceedings of the National Academy of Sciences of the United States of America·L SivaramanB W O'Malley
Mar 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Muhammad Al-HajjMichael F Clarke
Sep 16, 2003·Molecular and Cellular Biology·M A Christine PrattRobert Clarke
Dec 12, 2003·Nature Reviews. Cancer·Stephen R D Johnston, Mitch Dowsett
Dec 12, 2003·Nature Reviews. Cancer·Matthew Smalley, Alan Ashworth
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Donald A BerryEric P Winer
Sep 23, 2006·The New England Journal of Medicine·Craig T JordanMark Noble
Nov 14, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jens van WijngaardenClemens W G M Löwik
May 23, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R ConfortiF Andre
Jun 12, 2008·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·Emmanuelle Charafe-JauffretMax S Wicha
Dec 2, 2009·Methods in Molecular Biology·Xing-Jie LiangPaul C Wang
Jun 6, 2012·Journal of Mammary Gland Biology and Neoplasia·Frances L ShawRobert B Clarke
Jul 12, 2012·Oncology Letters·Xia KeZhi-Nan Chen
Dec 4, 2012·Genomics·Shatha AbuHammad, Malek Zihlif
May 21, 2013·Acta Pharmacologica Sinica·Ke ChenJi-long Chen
Oct 28, 2015·Advanced Pharmaceutical Bulletin·Simin SharifiNasser Samadi
Citations
Jul 7, 2019·Life Sciences·Maamoun FatfatHala Gali-Muhtasib
Nov 19, 2020·Oxidative Medicine and Cellular Longevity·José Eduardo VargasEduardo Filippi-Chiela
Jun 2, 2021·BMC Cancer·Joohyun WooWoosung Lim